↓ Skip to main content

Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Overview of attention for article published in Alzheimer's Research & Therapy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

news
1 news outlet
policy
1 policy source

Citations

dimensions_citation
73 Dimensions

Readers on

mendeley
93 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Diagnostic impact of [18F]flutemetamol PET in early-onset dementia
Published in
Alzheimer's Research & Therapy, January 2017
DOI 10.1186/s13195-016-0228-4
Pubmed ID
Authors

Marissa D. Zwan, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel, Philip Scheltens

Abstract

Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positron emission tomography (PET) imaging agent [(18)F]flutemetamol in early-onset dementia patients, in terms of change in (confidence in) diagnosis and patient management plan. This prospective bi-center study included 211 patients suspected of early-onset dementia who visited a tertiary memory clinic. Patients were eligible with Mini Mental State Examination ≥ 18 and age at diagnosis ≤ 70 years and in whom the diagnostic confidence was <90% after routine diagnostic work-up. All patients underwent [(18)F]flutemetamol PET, which was interpreted as amyloid-negative or amyloid-positive based on visual rating. Before and after disclosing the PET results, we assessed the diagnostic confidence (using a visual analog scale of 0-100%) and clinical diagnosis. The impact of [(18)F]flutemetamol PET on the patient management plan was also evaluated. [(18)F]flutemetamol PET scans were positive in 133 out of 211 (63%) patients, of whom 110 out of 144 (76%) patients had a pre-PET Alzheimer's disease (AD) diagnosis and 23 out of 67 (34%) patients had a non-AD diagnosis. After disclosure of PET results, 41/211 (19%) diagnoses changed. Overall, diagnostic confidence increased from 69 ± 12% to 88 ± 15% after disclosing PET results (P < 0.001; in 87% of patients). In 79 (37%) patients, PET results led to a change in patient management and predominantly the initiation of AD medication when PET showed evidence for amyloid pathology. [(18)F]flutemetamol PET changed clinical diagnosis, increased overall diagnostic confidence, and altered the patient management plan. Our results suggest that amyloid PET may have added value over the standardized diagnostic work-up in early-onset dementia patients with uncertain clinical diagnosis. This study provides evidence for the recommendations put forward in the appropriate use criteria for amyloid PET in clinical practice. Nederlands Trial Register NTR3743 . Registered 7 December 2012.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
United States 1 1%
Unknown 91 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 20%
Student > Master 16 17%
Researcher 15 16%
Other 13 14%
Student > Bachelor 7 8%
Other 14 15%
Unknown 9 10%
Readers by discipline Count As %
Medicine and Dentistry 29 31%
Neuroscience 12 13%
Psychology 11 12%
Nursing and Health Professions 4 4%
Physics and Astronomy 3 3%
Other 13 14%
Unknown 21 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2018.
All research outputs
#2,161,707
of 17,363,630 outputs
Outputs from Alzheimer's Research & Therapy
#483
of 890 outputs
Outputs of similar age
#58,032
of 365,517 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 17,363,630 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 890 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,517 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them